ORAL ONCOLOGY口腔肿瘤学
ORAL ONCOLOGY(英文缩写 ORAL ONCOL),ISSN 1368-8375,eISSN 1879-0593,中文译名:口腔肿瘤学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 5.972 | Q1 |
| 2022 | 4.800 | Q1 |
| 2023 | 4.000 | Q1 |
| 2024 | 3.900 | Q1 |
| 2025 | 4.000 | Q1 |
ORAL ONCOLOGY 最新收录文献
-
1. Exercise prehabilitation in head and neck cancer patients proposed for definitive chemoradiotherapy: The FIT4TREAT randomized controlled trial.
PMID:日期:2026-10-01Patients with head and neck cancer (HNC) initially scheduled for definitive chemoradiotherapy (CRT) often experience early functional decline and deterioration in health-related quality of life (HRQoL) even before treatment initiation. Evidence for prehabilitation in this non-surgical setting remains limited. This study evaluated whether exercise prehabilitation (EP) initiated before CRT improves functional capacity compared with usual care (UC). FIT4TREAT (ClinicalTrials.gov: NCT05418842) was a prospective, single-center, randomized clinical trial. Adults with HNC proposed for definitive CRT were randomly assigned (1:1) to EP or UC. EP consisted of supervised combined aerobic and resistance exercise performed three times per week from baseline until radiotherapy initiation. The primary outcome was the six-minute walk distance (6MWD) at the end of the pre-treatment period. Secondary outcomes included muscle strength, lower-limb functionality, body composition, and HRQoL assessed using the EORTC QLQ-C30 and QLQ-HN43. Between May 2021 and February 2025, 47 patients were enrolled; 40 were included in the primary analysis. After adjustment for baseline 6MWD and the randomization stratification variables, EP resulted in a significantly greater pre-treatment 6MWD than UC (adjusted between-group difference, 28.6 m; 95 % CI, 4.1-53.1; P = 0.023). EP also improved lower-limb functionality (P < 0.001) and was associated with better preservation in the QLQ-C30 summary score (P = 0.008), social functioning (P = 0.038) and body image (P = 0.011). EP before definitive CRT improves functional capacity and may help preserve HRQoL in patients with HNC, supporting its potential integration into routine oncology care.
-
2. Methodological concerns regarding "PD-L1 cutoff selection and predictive claims in the IT-MATTERS Trial".
PMID:日期:2026-10-01该文献暂无摘要。
-
3. Refining frailty stratification in elderly head and neck free flap reconstruction.
PMID:日期:2026-10-01该文献暂无摘要。
-
4. HPV circulating tumor DNA as a potential prognostic and predictive biomarker in head and neck squamous cell carcinoma: a systematic review.
PMID:日期:2026-10-01Human papillomavirus circulating tumor DNA (HPVctDNA) has emerged as a promising prognostic biomarker in HPV-related head and neck squamous cell carcinoma (HNSCC). This systematic review aimed to synthesize current evidence on the diagnostic accuracy and prognostic value of HPVctDNA in HNSCC management. We systematically reviewed a PubMed-indexed database of studies published between January 2012 and September 2025. Eligible studies were assessed for design, primary tumor site and stage, treatment modality, HPVctDNA detection method, diagnostic accuracy (sensitivity and specificity), and reported clinical endpoints. Descriptive syntheses were performed; sensitivity and specificity were standardized to proportions and summarized as median values per group. A total of 60 studies, including 8,234 patients were analyzed, of which 41 (68.3%) focused exclusively on oropharyngeal squamous cell carcinoma (OPSCC) and 17 (28.3%) included mixed HPV-related HNSCC subsites and HPV-positive cancers of unknown primary. The median follow-up across the included studies was 23 months. Among the included studies, 19 were retrospective (31.7%) and 33 were prospective (55.0%), with a small proportion of cross-sectional and randomized clinical trials. Overall, 40 (66.7%) evaluated the role of HPVctDNA in a curative setting. Plasma was the most common sample type, analyzed in 55 studies (91.7%), while 5 studies also included saliva. Detection methods varied: 40 employed droplet digital PCR (ddPCR), 16 used quantitative PCR (qPCR) and 4 applied NGS-based assays. Most of these studies (38, 63.3%) evaluated the prognostic utility of HPVctDNA, while only 4 (6.7%) assessed HPVctDNA in a screening or diagnostic setting. Regarding diagnostic accuracy, the median sensitivity across evaluable studies was 91.1%, while the median specificity was 99.4%. In OPSCC-only cohorts, the median sensitivity and specificity were 89.4% and 99.4%, respectively. Dynamic changes in HPVctDNA levels during or after treatment were consistently associated with outcomes: clearance or sustained negativity correlated with higher response rates, improved progression-free survival and overall survival, while persistent positivity or increasing levels predicted disease progression and recurrence. HPVctDNA demonstrates high diagnostic and prognostic accuracy in HPV-related HNSCC, especially OPSCC, supporting its use for prognosis, treatment monitoring and early detection of recurrence. However, prospective interventional studies are still required to demonstrate that HPVctDNA-guided treatment decisions improve clinical outcomes before routine implementation.
-
5. Radiation-associated dysphagia in head and neck cancer: A narrative review of surgical management, diagnosis, and emerging directions.
PMID:日期:2026-10-01Radiation-associated dysphagia (RAD) is a major short and long-term complication of treatment in head and neck cancer (HNC) patients associated with malnutrition, aspiration pneumonia, and markedly reduced quality of life. This review focuses exclusively on the management of RAD for the surgeon, emphasizing surgical techniques, functional rehabilitation, and emerging technologies. Post-operative dysphagia following surgical disease management (tumor resection, reconstruction, nerve injury) is an important but separate entity and is beyond the scope of this review. We discuss the pathophysiology of RAD, common clinical presentations, evidence-based surgical interventions, and future directions for study in optimizing post-radiotherapy swallowing function.
-
7. Real-world treatment sequences and outcomes in recurrent/metastatic head and neck squamous cell carcinoma in France (TERENCE study).
PMID:日期:2026-10-01Recurrent and/or metastatic head and neck squamous cell carcinoma (R/M SCCHN) is aggressive, with limited therapeutic options. Guidelines recommend immunotherapy (IO) or cetuximab ± chemotherapy 1-line, depending on patient/tumour characteristics. Data on subsequent treatment sequencing are limited. We investigated treatment sequences for R/M SCCHN in France. Patients with R/M SCCHN who received 1-line pembrolizumab or cetuximab (November 2020-December 2022) were identified retrospectively from a hospital discharge database, which covers 85% of the French population. Treatment sequences, overall survival (OS) and time to next treatment or death (TTNT-D) were analysed. Outcomes were compared between sequences of interest (pembrolizumab-based 1-line followed by cetuximab ± chemotherapy, or vice versa). Of 4757 patients who received 1-line IO or cetuximab, 2529 (53%) received 2-line. Fewer patients who received IO-based vs. cetuximab-based 1-line treatment received 2-line (45.4% vs. 61.5%): more on 1-line IO reached end of follow-up without 2-line (26.6% vs. 8.2%). 2-line/subsequent treatments were heterogeneous. For patients receiving ≥1 treatment line, median OS was 13.2 months overall (15.4 months for patients receiving ≥2 lines). For 1,742 patients who received sequences of interest, there were no significant differences between 1-line IO vs. cetuximab for OS (hazard ratio [HR] 0.98, [95%CI 0.90, 1.11], p=0.84) or TTNT-D (HR 0.92 [0.83, 1.03]. p=0.15). In this nationwide cohort study, OS did not differ significantly between patients who received IO followed by cetuximab vs. cetuximab followed by IO. These findings support flexibility in treatment sequencing and highlight the need for further research to optimize treatment strategies.
-
8. Late oral complications and assessment of oral symptoms in childhood and adolescent cancer survivors following head and neck radiotherapy: a cross-sectional study.
PMID:日期:2026-10-01The objective of this study was to evaluate the oral health, late oral complications, and oral symptoms in patients who underwent radiotherapy in the head and neck region during childhood and adolescence. Data were collected from a specialized pediatric oncology and hematology hospital; to assess oral health, measurements were taken of stimulated and unstimulated salivary flow, gingival bleeding index, visible plaque index, and caries activity index. Clinical data such as neoplasm type, treatment administered, and total radiation dose were collected. Additionally, the Vanderbilt Head and Neck Symptom Survey questionnaire was utilized to assess oral symptoms. A total of 52 patients were evaluated, with 53.8% being male and 46.2% female. The most frequent diagnosis was Hodgkin's Lymphoma (69.2%), and the most common late-onset alterations observed were trismus, prolonged retention of primary teeth, agenesis, and microdontia. Regarding salivary flow, 19.6% of patients exhibited hyposalivation with stimulated saliva, and 1.9% with unstimulated saliva. The mean visible plaque index was 7.8%, and the mean gingival bleeding index was 2.3%. In relation to the International Caries Detection and Assessment System score, 91.4% of the sample scored 0. In terms of oral symptom assessment, the domain labeled "dry mouth" was the most affected, with 18.9% of patients experiencing some degree of xerostomia. Patients who received radiotherapy for tumors in the head and neck during childhood and adolescence may develop late oral changes, which impact their oral symptoms.
-
9. Association of glycaemic control with post-radiation nasopharyngeal necrosis in diabetic patients with nasopharyngeal carcinoma.
PMID:日期:2026-10-01Post-radiation nasopharyngeal necrosis (PRNN) is a rare but life-threatening late complication in patients with nasopharyngeal carcinoma (NPC). Diabetes mellitus (DM) has been reported as a risk factor for PRNN; however, the impact of long-term glycaemic control on PRNN risk and severity remains unclear. We conducted a retrospective cohort study of diabetic patients with newly diagnosed NPC treated with intensity-modulated radiotherapy (IMRT) between 2019 and 2022. Long-term glycaemic control was assessed using hemoglobin A1c (HbA1c) levels obtained within 3 months prior to the initiation of radiotherapy and categorized as optimal (<7 %) or suboptimal (≥7 %). Propensity score matching (PSM) was applied to minimize confounding. Among 315 eligible patients, PRNN occurred in 43 (13.7 %) over a median follow-up of 39.7 months. After PSM, 232 patients were included. PRNN developed in 19.0 % of patients with suboptimal glycaemic control compared with 7.8 % of those with optimal control. Suboptimal glycaemic control was significantly associated with an increased risk of PRNN (odds ratio: 2.86, 95 % confidence interval: 1.21-6.76). Higher HbA1c levels were associated with progressively increased PRNN risk (P for trend < 0.0001) and greater necrosis severity. In addition, suboptimal glycaemic control was associated with inferior local recurrence-free, distant metastasis-free, progression-free, and overall survival (all P < 0.05). Poor glycaemic control is independently associated with increased risk and severity of PRNN and adverse survival outcomes in diabetic patients with NPC. These findings suggest that optimized glycaemic management may represent a clinically actionable strategy to reduce PRNN risk in this vulnerable population.